Search hospitals > Texas > Houston

Lyndon Baines Johnson General Hospital

Claim this profile
Houston, Texas 77026
Global Leader in Cancer
Global Leader in Adenocarcinoma
Conducts research for Recurrence
Conducts research for Endometrioid Carcinoma
Conducts research for Serous Cystadenocarcinoma
102 reported clinical trials
15 medical researchers
Photo of Lyndon Baines Johnson General Hospital in HoustonPhoto of Lyndon Baines Johnson General Hospital in HoustonPhoto of Lyndon Baines Johnson General Hospital in Houston

Summary

Lyndon Baines Johnson General Hospital is a medical facility located in Houston, Texas. This center is recognized for care of Cancer, Adenocarcinoma, Recurrence, Endometrioid Carcinoma, Serous Cystadenocarcinoma and other specialties. Lyndon Baines Johnson General Hospital is involved with conducting 102 clinical trials across 222 conditions. There are 15 research doctors associated with this hospital, such as Aung Naing, MD, Shannon Westin, MD, Michael J Overman, MD, and Vicente Valero, MD.

Area of expertise

1Cancer
Global Leader
Lyndon Baines Johnson General Hospital has run 40 trials for Cancer. Some of their research focus areas include:
Stage IV
HER2 positive
Stage III
2Adenocarcinoma
Global Leader
Lyndon Baines Johnson General Hospital has run 21 trials for Adenocarcinoma. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Top PIs

Clinical Trials running at Lyndon Baines Johnson General Hospital

Breast Cancer
Prostate Cancer
Fallopian Tube Cancer
Ovarian Cancer
Colorectal Cancer
Endometrial Adenocarcinoma
Rectal Cancer
Peritoneal Cancer
Recurrence
Adenocarcinoma
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib

for Breast Cancer

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
Recruiting2 awards Phase 312 criteria
Image of trial facility.

T-DM1 + Tucatinib

for Breast Cancer

This study is evaluating whether a combination of two drugs may help prevent breast cancer from coming back.
Recruiting1 award Phase 313 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Lyndon Baines Johnson General Hospital?
Lyndon Baines Johnson General Hospital is a medical facility located in Houston, Texas. This center is recognized for care of Cancer, Adenocarcinoma, Recurrence, Endometrioid Carcinoma, Serous Cystadenocarcinoma and other specialties. Lyndon Baines Johnson General Hospital is involved with conducting 102 clinical trials across 222 conditions. There are 15 research doctors associated with this hospital, such as Aung Naing, MD, Shannon Westin, MD, Michael J Overman, MD, and Vicente Valero, MD.